Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer …

This entry was posted by ctbenefits on March 9, 2016 at 12:46 AM

MINDACT is a phase III, randomized, prospective study comparing the use of MammaPrint 70-gene assay with clinical-pathological criteria (current standard of care) for selecting early breast cancer patients who should be treated with adjuvant chemotherapy.